(MedPage Today) -- The FDA approved the dopamine agonist tavapadon (Juvmo) to treat adults with Parkinson's disease, drugmaker AbbVie announced Monday.
Tavapadon is an oral selective D1/D5 dopamine agonist that was studied as monotherapy for early...